Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1% – What’s Next?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was down 6.1% on Friday . The company traded as low as $17.23 and last traded at $17.1480. Approximately 276,772 shares were traded during trading, a decline of 78% from the average daily volume of 1,231,678 shares. The stock had previously closed at $18.27.

Analysts Set New Price Targets

Several research analysts have recently commented on EYPT shares. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, October 8th. TD Cowen raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Friday, December 19th. Mizuho set a $28.00 price target on shares of Eyepoint Pharmaceuticals in a report on Monday, October 20th. Finally, Royal Bank Of Canada upped their price objective on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $30.00.

Eyepoint Pharmaceuticals Stock Down 4.3%

The business’s 50-day simple moving average is $14.94 and its two-hundred day simple moving average is $12.71. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -5.85 and a beta of 1.63.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.08). The company had revenue of $0.97 million for the quarter, compared to analysts’ expectations of $3.33 million. Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%. Sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Corient Private Wealth LLC acquired a new stake in Eyepoint Pharmaceuticals during the 2nd quarter worth approximately $1,200,000. Invesco Ltd. increased its position in shares of Eyepoint Pharmaceuticals by 174.3% during the first quarter. Invesco Ltd. now owns 42,948 shares of the company’s stock worth $233,000 after acquiring an additional 27,291 shares during the period. American Century Companies Inc. acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter valued at $232,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Eyepoint Pharmaceuticals by 127.8% in the first quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company’s stock valued at $397,000 after acquiring an additional 41,132 shares in the last quarter. Finally, Walleye Capital LLC boosted its holdings in Eyepoint Pharmaceuticals by 500.6% in the second quarter. Walleye Capital LLC now owns 199,449 shares of the company’s stock valued at $1,877,000 after purchasing an additional 166,243 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.